Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy.

Quantitative Systems Pharmacology (QSP) is an emerging science with increasing application to pharmaceutical research and development paradigms. Through case study we provide an overview of the benefits and challenges of applying QSP approaches to inform program decisions in the early stages of drug discovery and development. Specifically, we describe the use of a type 2 diabetes systems model to inform a No-Go decision prior to lead development for a potential GLP-1/GIP dual agonist program, enabling prioritization of exploratory programs with higher probability of clinical success.

[1]  B. Monz,et al.  A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus , 2013, BMJ Open.

[2]  P Vicini,et al.  Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers , 2015, CPT: pharmacometrics & systems pharmacology.

[3]  J. Holst,et al.  The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. , 2011, American journal of physiology. Endocrinology and metabolism.

[4]  John D. Davis,et al.  A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations , 2014, CPT: pharmacometrics & systems pharmacology.

[5]  B. Göke,et al.  The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes , 2012, Diabetes.

[6]  D. Yabe,et al.  GIP and GLP‐1, the two incretin hormones: Similarities and differences , 2010, Journal of diabetes investigation.

[7]  A. Mari,et al.  Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. , 2009, The Journal of clinical endocrinology and metabolism.

[8]  J. Holst,et al.  Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors , 2015, Diabetes, obesity & metabolism.

[9]  Marc R Gastonguay,et al.  Multiscale Physiology‐Based Modeling of Mineral Bone Disorder in Patients With Impaired Kidney Function , 2012, Journal of clinical pharmacology.

[10]  F. Tinahones,et al.  Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. , 2014, The Journal of clinical endocrinology and metabolism.

[11]  J. Holst,et al.  The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action , 2010, Diabetes.

[12]  Matthew M Riggs,et al.  A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.

[13]  P. H. van der Graaf,et al.  Integrated Pharmacometrics and Systems Pharmacology Model-Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis , 2012, CPT: pharmacometrics & systems pharmacology.

[14]  C. Mcintosh,et al.  GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis , 2012, PloS one.

[15]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[16]  P Vicini,et al.  Systems Pharmacology for Drug Discovery and Development: Paradigm Shift or Flash in the Pan? , 2013, Clinical pharmacology and therapeutics.

[17]  Jason A. Papin,et al.  Mechanistic systems modeling to guide drug discovery and development. , 2013, Drug discovery today.

[18]  Kanako Iwasaki,et al.  Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions , 2014, Diabetes.

[19]  S. Potkin,et al.  Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: Application to iloperidone , 2015, Journal of psychopharmacology.

[20]  David J. Klinke,et al.  Integrating Epidemiological Data into a Mechanistic Model of Type 2 Diabetes: Validating the Prevalence of Virtual Patients , 2008, Annals of Biomedical Engineering.

[21]  R. Seeley,et al.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents , 2014, Nature Medicine.

[22]  M. Bachmann,et al.  Vaccination against GIP for the Treatment of Obesity , 2008, PloS one.

[23]  J. Holst,et al.  GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes , 2011, Diabetes.

[24]  William J Jusko,et al.  Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. , 2009, Drug metabolism and pharmacokinetics.

[25]  F. Rubino,et al.  Gastric Inhibitory Peptide Controls Adipose Insulin Sensitivity via Activation of cAMP-response Element-binding Protein and p110β Isoform of Phosphatidylinositol 3-Kinase* , 2011, The Journal of Biological Chemistry.

[26]  M. Nauck,et al.  Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? , 2010, Diabetes.

[27]  M. Riggs,et al.  Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model , 2012, CPT: pharmacometrics & systems pharmacology.

[28]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[29]  Steven B Waters,et al.  Treatment with Sitagliptin or Metformin Does Not Increase Body Weight despite Predicted Reductions in Urinary Glucose Excretion , 2009, Journal of diabetes science and technology.

[30]  M. Karlsson,et al.  A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects , 2013, Journal of Pharmacokinetics and Pharmacodynamics.